Inflammation Peptides

A pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties.

A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery.

A naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects.

A thymic peptide approved in some countries for immune modulation, studied for viral infections and cancer adjunct therapy.

A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties.

A human antimicrobial peptide studied for innate immunity, wound healing, and biofilm disruption.

A semi-synthetic polysaccharide FDA-approved for interstitial cystitis and studied for joint health applications.

A non-erythropoietic EPO analog studied for nerve repair and neuropathic pain conditions.

A neuropeptide with broad neuroimmune functions, studied for inflammatory conditions and nerve repair.

A multi-peptide blend combining BPC-157, TB-500, GHK-Cu, and KPV for comprehensive tissue repair and anti-inflammatory support.

A combined formulation of BPC-157 and TB-500, the two most commonly paired tissue repair peptides.

A synthetic peptide tight junction regulator in clinical trials for celiac disease, designed to prevent intestinal permeability caused by gluten exposure.

A brain-targeting tetrapeptide studied for neuroprotection and targeted drug delivery to injured brain and spinal cord tissue.

An endogenous cardiovascular peptide that signals through the APJ receptor, studied for heart failure, cardiac repair, and cardioprotection with multiple synthetic analogs in clinical development.

The first FDA-approved targeted oral macrocyclic peptide — an IL-23 receptor antagonist for moderate-to-severe plaque psoriasis, marking a new era for oral peptide therapeutics.

A synthetic 15-amino-acid peptide derived from the IL-10 receptor alpha chain, granted FDA breakthrough therapy status for systemic lupus erythematosus (SLE) after Phase III trial success.

A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease.

A long-acting, once-weekly dual GLP-1 and GLP-2 receptor agonist peptide (Zealand Pharma) developed for obesity, uniquely pairing GLP-1-driven weight loss with GLP-2 activation intended to improve intestinal barrier function and reduce obesity-related low-grade inflammation; development was paused in November 2025.

A PEGylated cyclic-peptide inhibitor of complement component 3 (C3) built from two compstatin (Cp05) peptide domains bridged by a 40-kDa PEG chain; marketed as Empaveli/Aspaveli (subcutaneous, for paroxysmal nocturnal hemoglobinuria and, since July 2025, C3 glomerulopathy and primary IC-MPGN) and Syfovre (intravitreal, for geographic atrophy in age-related macular degeneration). It is one of the few complement-targeting therapeutic peptides to reach the market.

Difelikefalin (Korsuva in the U.S., Kapruvia in Europe) is a synthetic tetrapeptide built entirely from D-amino acids - D-Phe-D-Phe-D-Leu-D-Lys capped with a 4-aminopiperidine-4-carboxylic acid - that acts as a selective agonist at the kappa opioid receptor. Its defining property is what it cannot do: the molecule is hydrophilic and bulky enough that it does not meaningfully cross the blood-brain barrier, so it reaches kappa receptors on peripheral sensory nerve endings, keratinocytes and immune cells while leaving the central kappa receptors that produce dysphoria and hallucinations largely untouched. It has no activity at the mu opioid receptor, so it carries neither euphoria nor respiratory depression. In the Phase 3 KALM-1 and KALM-2 trials in hemodialysis patients with moderate-to-severe chronic-kidney-disease-associated pruritus, roughly 40-51% of difelikefalin-treated patients achieved a clinically meaningful (>=3-point) reduction on the 10-point Worst Itching Intensity NRS at 12 weeks versus roughly 20-28% on placebo. The FDA approved intravenous difelikefalin in August 2021; the EU approved it as Kapruvia in April 2022.